Loading
LENSAR, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Sept 2024.
LENSAR, Inc.: what insiders have been doing
Every trade that managers of LENSAR, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 4 insiders have disclosed 10 filings since 18 October 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Compared with its exchange (5,814 companies, median 19 filings), a count of 10 filings is below the norm. Our records for LENSAR, Inc. go back to 2022, with 15 purchases and no sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 58.4 m USD and net income at -34.3 m USD.
Insider buying of LENSAR, Inc. has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
71
Thresholds
n/a
Buy Volume
€88,133
15 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- +162.6%Entry US$4.70 · Close at T+365 US$12.34
- +38.0%Entry US$3.00 · Close at T+365 US$4.14
- -29.8%Entry US$3.22 · Close at T+365 US$2.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate LENSAR, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$11.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,891 of 24,148 companies
21.5
score / 100
Value8
Quality35
FCF yld-18%
Earn yld-42%
EV/EBITDA·
ROE·
Gross mgn46%
Net mgn-59%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.57
Analyst consensus
3 analystsStrong buy
US$10.00Target US$11.33(+73%)US$13.00
Income statement
RevenueUS$58.4M
Gross profitUS$27.1M46% margin
EBITDA-US$20.1M-34% margin
Net income-US$34.3M57.6% margin
Valuation
PER (trailing)32.9x
PER (forward)-12.9x
P/Book5.4x
Beta0.97
Balance sheet & cash
Market capUS$80.7M
Total debtUS$2.7M
Free Cash Flow-US$14.9M
Debt / Equity8%
Profitability & ownership
ROE357.3%
ROA-18.7%
% insiders21.5%
% institutions46.0%
Last declaration on 5 June 2026
Declarations71 total
17,421 shares0Common StockSEC:0001193125-26-260332:0
130,662 shares0Common StockSEC:0001193125-26-259999:0
34,843 shares0Common StockSEC:0001193125-26-260001:0
5,500 shares@ US$2.6516.3% of flowCommon StockSEC:0001193125-26-116117:0
2,392 shares@ US$11.3242.0% of flowCommon StockSEC:0001193125-26-061468:0
1,076 shares@ US$11.3213.2% of flowCommon StockSEC:0001193125-26-061464:0
00Common StockSEC:0001193125-26-061457:0
1,826 shares@ US$11.5723.3% of flowCommon StockSEC:0001193125-26-011796:0
2,262 shares@ US$11.5741.2% of flowCommon StockSEC:0001193125-26-011795:0
00Common StockSEC:0001193125-26-011798:0
7,374 shares0Common StockSEC:0000950170-25-078409:0
7,374 shares0Common StockSEC:0000950170-25-078407:0
7,374 shares0Common StockSEC:0000950170-25-078369:0
7,374 shares0Common StockSEC:0000950170-25-078370:0
7,374 shares0Common StockSEC:0000950170-25-078371:0
7,374 shares0Common StockSEC:0000950170-25-078372:0
7,374 shares0Common StockSEC:0000950170-25-078373:0
127,660 shares0Common StockSEC:0000950170-25-024334:0
37,234 shares0Common StockSEC:0000950170-25-024338:0
12,766 shares0Common StockSEC:0000950170-25-024336:0
6,383 shares0Common StockSEC:0000950170-25-024335:0
1,839 shares@ US$8.2518.9% of flowCommon StockSEC:0000950170-25-015541:0
1,132 shares@ US$8.25100.0% of flowCommon StockSEC:0000950170-25-015543:0
685 shares@ US$4.508.6% of flowCommon StockSEC:0000950170-24-104242:0
Canonical exit: 2 Dec 2024 (T+90)
802 shares@ US$4.5810.2% of flowCommon StockSEC:0000950170-24-101573:0
Canonical exit: 24 Nov 2024 (T+90)
25 of 71 declarations
About LENSAR, Inc.
LENSAR, Inc. is a U.S.-based medical technology company listed on the Nasdaq market in the United States under the ticker LNSR. For French-speaking investors, it is best understood as a focused ophthalmic device business specializing in laser-assisted cataract surgery and robotic workflow automation. Headquartered in Orlando, Florida, the company combines product development, clinical support, commercialization, and the sale of installed systems to cataract surgeons.
Founded in the 2000s, LENSAR was built around a clear thesis: improve the precision, efficiency, and reproducibility of cataract surgery through advanced laser platforms. Its legacy product, the LENSAR Laser System, established the company’s technology base. More recently, the company introduced ALLY, an adaptive robotic cataract treatment system designed to cover multiple steps of the procedure and streamline the surgical workflow. LENSAR’s stated mission is centered on better patient outcomes through robotic laser technology, which frames the company’s commercial and clinical positioning.
Read moreShow less
From a competitive standpoint, LENSAR operates in a specialized segment of ophthalmic surgical devices and competes against larger, better-capitalized peers in eye care. Its position is that of a niche innovator, with a value proposition built on procedural precision, surgeon usability, and workflow efficiency. While its commercial footprint is smaller than that of global ophthalmology leaders, the company is working to expand adoption of ALLY and broaden its installed base in the United States and internationally.
Its key products and services include cataract laser systems, related disposables, and, depending on the commercial model, recurring revenue tied to the installed base. In 2025, LENSAR reported approximately 150 ALLY systems installed and more than 1 million procedures performed worldwide, which suggests a platform with meaningful commercial validation, even if the company remains in an early-to-mid growth and profitability development phase. LENSAR also received FDA clearance for ALLY, an important regulatory and commercial milestone.
Recent headlines were dominated by the company’s 2025 definitive merger agreement with Alcon and the later termination of that agreement in March 2026. For investors, that sequence highlights both the strategic value of the asset and the uncertainty that can surround its capital structure and ownership trajectory. Overall, LENSAR remains a speculative growth name within medtech, with exposure to clinical adoption trends, regulatory execution, competition, and financing needs.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
